Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Persse T, Galipeau P, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Ajkunic A, et al. Among authors: yu ey. NPJ Precis Oncol. 2024 May 17;8(1):104. doi: 10.1038/s41698-024-00599-6. NPJ Precis Oncol. 2024. PMID: 38760413 Free PMC article.
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Scher HI, et al. Among authors: yu ey. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14. Lancet. 2010. PMID: 20398925 Free PMC article. Clinical Trial.
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Yu EY, et al. J Clin Oncol. 2010 Jun 1;28(16):2668-73. doi: 10.1200/JCO.2009.25.1330. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421544 Free PMC article. Clinical Trial.
Advanced clinical states in prostate cancer.
Cheng HH, Lin DW, Yu EY. Cheng HH, et al. Among authors: yu ey. Urol Clin North Am. 2012 Nov;39(4):561-71. doi: 10.1016/j.ucl.2012.07.011. Epub 2012 Sep 12. Urol Clin North Am. 2012. PMID: 23084531 Review.
Long-term survival in bone-predominant metastatic urothelial carcinoma.
Ramos JD, Cheng HH, Yu EY. Ramos JD, et al. Among authors: yu ey. Clin Genitourin Cancer. 2014 Dec;12(6):e241-4. doi: 10.1016/j.clgc.2014.07.005. Epub 2014 Jul 23. Clin Genitourin Cancer. 2014. PMID: 25160520 Free PMC article. No abstract available.
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, Yu EY. Kuo KF, et al. Among authors: yu ey. Clin Genitourin Cancer. 2015 Feb;13(1):10-6. doi: 10.1016/j.clgc.2014.08.003. Epub 2014 Aug 10. Clin Genitourin Cancer. 2015. PMID: 25242417 Free PMC article. Clinical Trial.
411 results